Yu

Cooley advised Laekna (HKSE: 2105.HK), global biotech company focused on novel drug development for metabolic and cancer diseases, on its clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a treatment for obesity.

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.